CoChat

The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality

Open access
Karlsen, Tom H, Sheron, Nick, Zelber-Sagi, Shira, Carrieri, Patrizia, Dusheiko, Geoffrey, Bugianesi, Elisabetta, Pryke, Rachel, Hutchinson, Sharon J, Sangro, Bruno, Martin, Natasha K, Cecchini, Michele, Dirac, Mae Ashworth, Belloni, Annalisa, Serra-Burriel, Miquel, Ponsioen, Cyriel Y, Sheena, Brittney, Lerouge, Alienor, Devaux, Marion, Scott, Nick, Hellard, Margaret, Verkade, Henkjan J, Sturm, Ekkehard, Marchesini, Giulio, Yki-Järvinen, Hannele, Byrne, Chris D, Targher, Giovanni, Tur-Sinai, Aviad, Barrett, Damon, Ninburg, Michael, Reic, Tatjana, Taylor, Alison, Rhodes, Tim, Treloar, Carla, Petersen, Claus, Schramm, Christoph, Flisiak, Robert, Simonova, Marieta Y, Pares, Albert, Johnson, Philip, Cucchetti, Alessandro, Graupera, Isabel, Lionis, Christos, Pose, Elisa, Fabrellas, Núria, Ma, Ann T, Mendive, Juan M, Mazzaferro, Vincenzo, Rutter, Harry, Cortez-Pinto, Helena, Kelly, Deirdre, Burton, Robyn, Lazarus, Jeffrey V, Ginès, Pere, Buti, Maria, Newsome, Philip N, Burra, Patrizia, Manns, Michael P · 2022 · The Lancet

The DOI matches its Crossref record; 374 of the 377 references it cites were found in a registry or an index, and 1 are not checked yet.

Abstract

Liver diseases have become a major health threat across Europe, and the face of European hepatology is changing due to the cure of viral hepatitis C and the control of chronic viral hepatitis B, the increasingly widespread unhealthy use of alcohol, the epidemic of obesity, and undiagnosed or untreated liver disease in migrant populations.Consequently, Europe is facing a looming syndemic, in which socioeconomic and health inequities combine to adversely affect liver disease prevalence, outcomes, and opportunities to receive care.In addition, the COVID-19 pandemic has magnified pre-existing challenges to uniform implementation of policies and equity of access to care in Europe, arising from national borders and the cultural and historical heterogeneity of European societies.In following up on work from the Lancet Commission on liver disease in the UK and epidemiological studies led by the European Association for the Study of the Liver (EASL), our multidisciplinary Commission, comprising a wide range of public health, medical, and nursing specialty groups, along with patient representatives, set out to provide a snapshot of the European landscape on liver diseases and to propose a framework for the principal actions required to improve liver health in Europe.We believe that a joint European process of thinking, and construction of uniform policies and action, implementation, and evaluation can serve as a powerful mechanism to improve liver care in Europe and set the way for similar changes globally.On the basis of these data, we present ten actionable recommendations, half of which are oriented towards health-care providers and half of which focus primarily on health policy.A fundamental shift must occur, in which health promotion, prevention, proactive casefinding, early identification of progressive liver fibrosis, and early treatment of liver diseases replace the current emphasis on the management of end-stage liver disease complications.A considerable focus should be put on underserved and marginalised communities, including early diagnosis and management in children, and we provide proposals on how to better target disadvantaged communities through health promotion, prevention, and care using multilevel interventions acting on current barriers.Underlying this transformative shift is the need to enhance awareness of the preventable and treatable nature of many liver diseases.Therapeutic nihilism, which is prevalent in current clinical practice across a range of medical specialities as well as in many patients themselves, has to end.We wish to challenge medical specialty protectionism and invite a broad range of stakeholders, including primary care physicians, nurses, patients, peers, and members of relevant communities, along with medical specialists trained in obesity, diabetes, liver disease, oncology, cardiovascular disease, public health, addictions, infectious diseases, and more, to engage in integrated person-centred liver patient care across classical medical specialty boundaries.This shift includes a revision in how we converse about liver disease and speak with our patients, and a reappraisal of disease-related medical nomenclature conducted to increase awareness and reduce the social stigmatisation associated with liver disease.Reimbursement mechanisms and insurance systems must be harmonised to account for patient-centric, multimorbidity models of care across a range of medical specialties, and the World Health Assembly resolution to improve the transparency and fairness of market prices for medicines throughout Europe should be reinforced.Finally, we outline how Europe can move forward with implementation of effective policy action on taxation, food reformulation, and product labelling, advertising, and availability, similar to that implemented for tobacco, to reduce consumption of alcohol, ultraprocessed foods, and foods with added sugar, especially among young people.We should utilise the window of opportunity created by the COVID-19 pandemic to overcome fragmentation and the variability of health prevention policies and research across Europe.We argue that the liver is a window to the 21st-century health of the European population.Through our proposed syndemic approach to liver disease and social and health inequities in Europe, the liver will serve as a sentinel for improving the overall health of European populations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(21)01701-3

Cites

374 of 375 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Distribution of age of death in diseases typically related to smoking, obesity, and alcohol Percentage of overall deaths within 5-year age bands from specified diseases related to smoking, obesity, and alcohol intake (with the relevant ICD-10 codes). Patients die from alcohol-related liver disease in their 30s, 40s, and 50s, whereas deaths from smoking-related and obesity-related illness typically occur at a much later age (appendix p 11). Analysis by Nick Sheron. ICD=International Classification of Diseases.
Figure 1 Distribution of age of death in diseases typically related to smoking, obesity, and alcohol Percentage of overall deaths within 5-year age bands from specified diseases related to smoking, obesity, and alcohol intake (with the relevant ICD-10 codes). Patients die from alcohol-related liver disease in their 30s, 40s, and 50s, whereas deaths from smoking-related and obesity-related illness typically occur at a much later age (appendix p 11). Analysis by Nick Sheron. ICD=International Classification of Diseases.CC-BY-NC-SA · From the PDF
Figure 2 Potential years of working life lost and leading causes by WHO region
Figure 2 Potential years of working life lost and leading causes by WHO regionCC-BY-NC-SA · From the PDF
Figure 3 Liver-related mortality trajectories in countries of the WHO European region
Figure 3 Liver-related mortality trajectories in countries of the WHO European regionCC-BY-NC-SA · From the PDF
Figure 4 Risk factors, interventions, and disease progression for different liver diseases
Figure 4 Risk factors, interventions, and disease progression for different liver diseasesCC-BY-NC-SA · From the PDF
Image 5
CC-BY-NC-SA · From the PDF
Figure 6 Epidemiology of primary liver cancer due to NASH in the WHO European region, 1990 vs 2019
Figure 6 Epidemiology of primary liver cancer due to NASH in the WHO European region, 1990 vs 2019CC-BY-NC-SA · From the PDF
Figure 7 Obesity, alcohol consumption, and liver disease in Europe
Figure 7 Obesity, alcohol consumption, and liver disease in EuropeCC-BY-NC-SA · From the PDF
Figure 9 Premature deaths due to liver diseases, average 2020-50
Figure 9 Premature deaths due to liver diseases, average 2020-50CC-BY-NC-SA · From the PDF
Figure 10 Health and economic impact of different health policies
Figure 10 Health and economic impact of different health policiesCC-BY-NC-SA · From the PDF
Figure 11 Investment and return on investment from HCV elimination in the WHO European region, 2020-50 (A) Cost of testing, treatment, and health care for elimination and status quo scenarios. (B) Annual economic productivity gains from elimination compared to the status quo. (C) Net economic benefit of hepatitis C elimination compared to the status quo (includes testing, treatment, health care, and productivity costs). Costs and disease-adjusted life years discounted at 3% per year. Solid line and shading represent median and IQR of multiple uncertainty simulations (appendix pp 57-72). HCV=hepatitis C virus.
Figure 11 Investment and return on investment from HCV elimination in the WHO European region, 2020-50 (A) Cost of testing, treatment, and health care for elimination and status quo scenarios. (B) Annual economic productivity gains from elimination compared to the status quo. (C) Net economic benefit of hepatitis C elimination compared to the status quo (includes testing, treatment, health care, and productivity costs). Costs and disease-adjusted life years discounted at 3% per year. Solid line and shading represent median and IQR of multiple uncertainty simulations (appendix pp 57-72). HCV=hepatitis C virus.CC-BY-NC-SA · From the PDF
Figure 12 Mortality rates for all liver disease (underlying cause) by local authority in northwest England and IMD score, 2006-10
Figure 12 Mortality rates for all liver disease (underlying cause) by local authority in northwest England and IMD score, 2006-10CC-BY-NC-SA · From the PDF
Figure 13 Obesity and type 2 diabetes by socioeconomic status in selected European countries, 2017 Data are from the Survey of Health, Ageing and Retirement in Europe (SHARE) showing the prevalence of obesity (A) and type 2 diabetes (B) in individuals aged 50-65 years with a low or a high household economic capacity from selected European countries in 2017. A person with diabetes was specified on the basis of a questionnaire. Obesity was defined as a body-mass index of 30 kg/m² or more. Economic status definition was based on an assessment of household economic capacity, with two potential situations: make ends meet with difficulty and make ends meet easily (appendix pp 14-15).
Figure 13 Obesity and type 2 diabetes by socioeconomic status in selected European countries, 2017 Data are from the Survey of Health, Ageing and Retirement in Europe (SHARE) showing the prevalence of obesity (A) and type 2 diabetes (B) in individuals aged 50-65 years with a low or a high household economic capacity from selected European countries in 2017. A person with diabetes was specified on the basis of a questionnaire. Obesity was defined as a body-mass index of 30 kg/m² or more. Economic status definition was based on an assessment of household economic capacity, with two potential situations: make ends meet with difficulty and make ends meet easily (appendix pp 14-15).CC-BY-NC-SA · From the PDF
Figure 14 Health Behaviour in School-aged Children survey in Europe Data are from the Health Behaviour in School-aged Children 2017-18 survey in the European region. Only the comparison between low-affluence and highaffluence categories are presented. The Pearson χ² test was used to examine the differences in overweight and eating behaviours between affluence categories. All p values were significant (<0·001; appendix pp 15-18).
Figure 14 Health Behaviour in School-aged Children survey in Europe Data are from the Health Behaviour in School-aged Children 2017-18 survey in the European region. Only the comparison between low-affluence and highaffluence categories are presented. The Pearson χ² test was used to examine the differences in overweight and eating behaviours between affluence categories. All p values were significant (<0·001; appendix pp 15-18).CC-BY-NC-SA · From the PDF
Figure 15 Types of stigma and their consequences with example interventions
Figure 15 Types of stigma and their consequences with example interventionsCC-BY-NC-SA · From the PDF
Figure 16 Survival rates for individuals following a first admission with liver failure
Figure 16 Survival rates for individuals following a first admission with liver failureCC-BY-NC-SA · From the PDF
Figure 17 Comparison of standard blood test results in patients in the CIRRUS dataset
Figure 17 Comparison of standard blood test results in patients in the CIRRUS datasetCC-BY-NC-SA · From the PDF
Figure 18 Survival rates of series of patients from areas with different implementation of hepatocellular carcinoma screening activities The figure shows the effect of screening on survival rates. High: Ogaki (Japan); intermediate: Birmingham, Newcastle, and Pamplona (Europe); low: Hong Kong (China; appendix p 19).
Figure 18 Survival rates of series of patients from areas with different implementation of hepatocellular carcinoma screening activities The figure shows the effect of screening on survival rates. High: Ogaki (Japan); intermediate: Birmingham, Newcastle, and Pamplona (Europe); low: Hong Kong (China; appendix p 19).CC-BY-NC-SA · From the PDF
Figure 19 A template for stratification of individuals at risk of liver disease for non-hepatologists
Figure 19 A template for stratification of individuals at risk of liver disease for non-hepatologistsCC-BY-NC-SA · From the PDF
Figure 20 European liver transplants attributable to viral causes Data plotted with permission from the European Liver Transplant Registry.
Figure 20 European liver transplants attributable to viral causes Data plotted with permission from the European Liver Transplant Registry.CC-BY-NC-SA · From the PDF
Figure 22 Association between the price of alcohol and liver death rates across selected European countries in 2010
Figure 22 Association between the price of alcohol and liver death rates across selected European countries in 2010CC-BY-NC-SA · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 375 references

Research works printed but not linked: 7

  1. Sze, 2020, Ethnicity and clinical outcomes in COVID-19: a systematic review and meta-analysis, EClinicalMedicine, 29
  2. Tan, 2020, Obesity and covid-19: the role of the food industry, BMJ, 369
  3. Harrison, 2016, Assessment and management of cirrhosis in people older than 16 years: summary of NICE guidance, BMJ, 354
  4. Boettler, 2020, Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper, JHEP Rep, 2
  5. Burton, 2017, A rapid evidence review of the effectiveness and cost-effectiveness of alcohol control policies: an English perspective, Lancet, 389, 1558, 10.1016/s0140-6736(16)32420-5 · DOI · Paper page
  6. Chaillon, 2019, Cost-effectiveness of universal hepatitis C virus screening of pregnant women in the United States, Clin Infect Dis, 69, 1888, 10.1093/cid/ciz063 · DOI
  7. Heffernan, 2019, Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model, Lancet, 393, 1319, 10.1016/s0140-6736(18)32277-3 · DOI · Paper page

Cited by

See all 737

Metadata

Authors
Karlsen, T. H., Sheron, N., Zelber-Sagi, S., Carrieri, P., Dusheiko, G., Bugianesi, E., Pryke, R., Hutchinson, S. J., Sangro, B., Martin, N. K., Cecchini, M., Dirac, M. A., Belloni, A., Serra-Burriel, M., Ponsioen, C. Y., Sheena, B., Lerouge, A., Devaux, M., Scott, N., Hellard, M., Verkade, H. J., Sturm, E., Marchesini, G., Yki-Järvinen, H., Byrne, C. D., Targher, G., Tur-Sinai, A., Barrett, D., Ninburg, M., Reic, T., Taylor, A., Rhodes, T., Treloar, C., Petersen, C., Schramm, C., Flisiak, R., Simonova, M. Y., Pares, A., Johnson, P., Cucchetti, A., Graupera, I., Lionis, C., Pose, E., Fabrellas, N., Ma, A. T., Mendive, J. M., Mazzaferro, V., Rutter, H., Cortez-Pinto, H., Kelly, D., Burton, R., Lazarus, J. V., Ginès, P., Buti, M., Newsome, P. N., Burra, P., & Manns, M. P.
Affiliations
  • Oslo University Hospital (NO)
  • King's College London (GB)
  • University of Haifa (IL)
  • Inserm (FR)
  • King's College Hospital (GB)
  • University of Turin (IT)
  • Glasgow Caledonian University (GB)
  • Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (ES)
  • University of Bristol (GB)
  • Organisation de Coopération et de Développement Economiques (FR)
  • University of Washington (US)
  • Public Health England (GB)
  • Amsterdam UMC Location University of Amsterdam (NL)
  • Burnet Institute (AU)
  • University Medical Center Groningen (NL)
  • University Children's Hospital Tübingen (DE)
  • IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola (IT)
  • University of Helsinki (FI)
  • University of Verona (IT)
  • University of Gothenburg (SE)
  • Childrens Liver Disease Foundation (GB)
  • London School of Hygiene & Tropical Medicine (GB)
  • UNSW Sydney (AU)
  • Medizinische Hochschule Hannover (DE)
  • University Medical Center Hamburg-Eppendorf (DE)
  • Medical University of Białystok (PL)
  • Military Medical Academy (BG)
  • Hospital Clínic de Barcelona (ES)
  • University of Liverpool (GB)
  • University of Bologna (IT)
  • University of Crete (GR)
  • Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
  • Instituto de Salud Carlos III (ES)
  • University of Milan (IT)
  • University of Bath (GB)
  • Birmingham Women's Hospital (GB)
  • University Hospitals Birmingham NHS Foundation Trust (GB)
  • Azienda Ospedale - Università Padova (IT)
Corresponding author
Karlsen, Tom H
Venue
The Lancet
Publisher
Elsevier BV
Published
2022-01
Volume
399
Issue
10319
Pages
61-116
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W4200536452
Cited by
652
References
377
Citations by year
2026: 96 · 2025: 168 · 2024: 147 · 2023: 142 · 2022: 94
FWCI
14.85
Type
journal article
Language
en
Open access
Locations
  • The Lancet (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion, other-oa)
  • ePrints Soton (University of Southampton) (acceptedVersion)
  • ResearchOnline (Glasgow Caledonian University) (acceptedVersion, cc-by-nc-nd)
  • Pure (University of Bath) (submittedVersion, cc-by-nc-nd)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • HAL (submittedVersion)
  • Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
  • Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, cc-by-nc-nd)
  • Deposito Adademico Digital Universidad De Navarra (University of Navarra) (submittedVersion, other-oa)
  • University of Birmingham Research Portal (University of Birmingham) (submittedVersion, other-oa)
  • University of Birmingham Research Portal (University of Birmingham) (submittedVersion, cc-by-nc-nd)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
  • Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion)
  • UNSWorks (UNSW Sydney) (submittedVersion, cc-by)
  • NORA - Norwegian Open Research Archives (submittedVersion, cc-by-nc-nd)
  • Padua Research Archive (University of Padova) (submittedVersion, cc-by-nc-sa)
Funders
  • European Commission
  • French National Research Agency
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
Keywords
liver disease, health disparities, liver fibrosis, early diagnosis, liver disease prevention, health promotion, migrants, obesity, alcohol consumption, viral hepatitis, COVID-19 pandemic, therapeutic nihilism, person-centred care, multidisciplinary care, Europe
MeSH terms
Europe, Health Policy, Humans, Liver Diseases, Mortality, Premature

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. https://app.cochat.ai/papers/10.1016/s0140-6736(21)01701-3
The paper
Karlsen, T. H., Sheron, N., Zelber-Sagi, S., Carrieri, P., Dusheiko, G., Bugianesi, E., Pryke, R., Hutchinson, S. J., Sangro, B., Martin, N. K., Cecchini, M., Dirac, M. A., Belloni, A., Serra-Burriel, M., Ponsioen, C. Y., Sheena, B., Lerouge, A., Devaux, M., Scott, N., . . . Manns, M. P. (2022). The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. The Lancet. https://doi.org/10.1016/s0140-6736(21)01701-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.